{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949708",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949708_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atomoxetine\" outputclass=\"int-drug\">atomoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   atomoxetine .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atomoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949709",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949709_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"cimetidine\" outputclass=\"int-drug\">Cimetidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dacomitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219440\">dacomitinib</xref></ph> should be taken 2 hours before or 10 hours after <ph otherprops=\"cimetidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/cimetidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP404\">cimetidine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Cimetidine   is predicted to   decrease   the concentration of   dacomitinib .  Manufacturer advises  dacomitinib  should be taken 2 hours before or 10 hours after  cimetidine .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cimetidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949710",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949710_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eliglustat\" outputclass=\"int-drug\">eliglustat</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   eliglustat .  Manufacturer advises avoid or adjust dose—consult product literature .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eliglustat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949711",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949711_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"esomeprazole\" outputclass=\"int-drug\">Esomeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Esomeprazole   is predicted to   decrease   the exposure to   dacomitinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esomeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949712",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949712_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"famotidine\" outputclass=\"int-drug\">Famotidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dacomitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219440\">dacomitinib</xref></ph> should be taken 2 hours before or 10 hours after <ph otherprops=\"famotidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/famotidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP407\">famotidine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Famotidine   is predicted to   decrease   the concentration of   dacomitinib .  Manufacturer advises  dacomitinib  should be taken 2 hours before or 10 hours after  famotidine .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Famotidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949713",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949713_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   imipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949714",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949714_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lansoprazole\" outputclass=\"int-drug\">Lansoprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lansoprazole   is predicted to   decrease   the exposure to   dacomitinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lansoprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949715",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949715_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"metoprolol\" outputclass=\"int-drug\">metoprolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   metoprolol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949716",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949716_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nebivolol\" outputclass=\"int-drug\">nebivolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   nebivolol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nebivolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949717",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949717_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"nizatidine\" outputclass=\"int-drug\">Nizatidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dacomitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219440\">dacomitinib</xref></ph> should be taken 2 hours before or 10 hours after <ph otherprops=\"nizatidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/nizatidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP410\">nizatidine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Nizatidine   is predicted to   decrease   the concentration of   dacomitinib .  Manufacturer advises  dacomitinib  should be taken 2 hours before or 10 hours after  nizatidine .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nizatidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949718",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949718_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   nortriptyline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949719",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949719_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"omeprazole\" outputclass=\"int-drug\">Omeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Omeprazole   is predicted to   decrease   the exposure to   dacomitinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949720",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949720_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pantoprazole\" outputclass=\"int-drug\">Pantoprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pantoprazole   is predicted to   decrease   the exposure to   dacomitinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pantoprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949721",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949721_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   propranolol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949722",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949722_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rabeprazole\" outputclass=\"int-drug\">Rabeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rabeprazole   is predicted to   decrease   the exposure to   dacomitinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rabeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949723",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949723_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"ranitidine\" outputclass=\"int-drug\">Ranitidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">dacomitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dacomitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219440\">dacomitinib</xref></ph> should be taken 2 hours before or 10 hours after <ph otherprops=\"ranitidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ranitidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP413\">ranitidine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Ranitidine   is predicted to   decrease   the concentration of   dacomitinib .  Manufacturer advises  dacomitinib  should be taken 2 hours before or 10 hours after  ranitidine .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949724",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2#bnf_i1643857949724_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dacomitinib\" outputclass=\"int-heading-drug\">Dacomitinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dacomitinib   is predicted to   markedly   increase   the exposure to   tolterodine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				}
			],
			"hasSearchLabel": " Dacomitinib  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/dacomitinib-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Dacomitinib </title>"
			},
			"rdfs:label": "dacomitinib"
		}
	]
}